PepperLime Health Acquisition Corp: Nasdaq/NYSE listing notice — PepperLime Health receives second Nasdaq delisting notice for MVLS non-compliance

PepperLime Health Acquisition Corp

Received MVLS notice on April 6, 2023 for failing $50M market value of listed securities.
Has 180 days (until Oct 3, 2023) to regain compliance; no immediate delisting effect.
Also previously received MVPHS notice on Feb 28, 2023 for $15M market value of publicly held shares.
May transfer to Nasdaq Capital Market if unable to regain compliance on Global Market.
No assurance of regaining compliance or avoiding eventual delisting.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PepperLime Health Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C), 5810(c)(3)(D)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5450(b)(2)(C), 5810(c)(3)(D)

Exact text from the filing

April 6, 2023, PepperLime Health Acquisition Corporation (the “ Company ”) received a second notice (the “ MVLS Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company’s listed securities failed to comply with the $50 million market value of listed securities (“ Market Value of Listed Securities ”) requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(2)(A) based upon the Company’s Market Value of Listed Securities for the 30 consecutive business days prior to the date of the MVLS Notice. The MVLS Notice has no im

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-044584

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.